牛牛AI助理已提取核心訊息
In8bio, a clinical-stage biopharmaceutical company, has filed a prospectus related to the resale of up to 42,703,475 shares of common stock by selling stockholders. The shares include those issued in a private placement on December 13, 2023, and others pursuant to an Investors' Rights Agreement dated May 7, 2018. The company will not sell any shares or receive proceeds from the stockholders' sales but will receive proceeds from any exercised warrants for cash. The shares may be sold at market prices or negotiated prices through various methods, including underwriters, broker-dealers, or agents. In8bio's common stock is listed on the Nasdaq Global Market under the symbol 'INAB.' As of January 17, 2024, the stock was priced at $1.52 per share. The company, which focuses on gamma-delta T cell therapies for cancer, is considered an 'emerging growth company' and a 'smaller reporting company,' with certain reduced public company reporting requirements. The prospectus also highlights the risks associated with investing in In8bio's securities.
In8bio, a clinical-stage biopharmaceutical company, has filed a prospectus related to the resale of up to 42,703,475 shares of common stock by selling stockholders. The shares include those issued in a private placement on December 13, 2023, and others pursuant to an Investors' Rights Agreement dated May 7, 2018. The company will not sell any shares or receive proceeds from the stockholders' sales but will receive proceeds from any exercised warrants for cash. The shares may be sold at market prices or negotiated prices through various methods, including underwriters, broker-dealers, or agents. In8bio's common stock is listed on the Nasdaq Global Market under the symbol 'INAB.' As of January 17, 2024, the stock was priced at $1.52 per share. The company, which focuses on gamma-delta T cell therapies for cancer, is considered an 'emerging growth company' and a 'smaller reporting company,' with certain reduced public company reporting requirements. The prospectus also highlights the risks associated with investing in In8bio's securities.
臨床階段的生物製藥公司in8bio已提交了一份招股說明書，內容涉及通過出售股東轉售多達42,703,475股普通股。這些股票包括2023年12月13日私募發行的股票，以及根據2018年5月7日投資者權利協議發行的其他股票。公司不會出售任何股票或從股東的出售中獲得收益，但將從任何行使的認股權證中獲得現金收益。股票可以通過各種方法（包括承銷商、經紀交易商或代理商）以市場價格或協議價格出售。In8bio的普通股在納斯達克全球市場上市，股票代碼爲 “INAB”。截至2024年1月17日，該股的定價爲每股1.52美元。該公司專注於癌症的伽瑪三角洲T細胞療法，被視爲 “新興成長型公司” 和 “規模較小的申報公司”，上市公司的報告要求有所降低。招股說明書還強調了與投資In8bio證券相關的風險。
臨床階段的生物製藥公司in8bio已提交了一份招股說明書，內容涉及通過出售股東轉售多達42,703,475股普通股。這些股票包括2023年12月13日私募發行的股票，以及根據2018年5月7日投資者權利協議發行的其他股票。公司不會出售任何股票或從股東的出售中獲得收益，但將從任何行使的認股權證中獲得現金收益。股票可以通過各種方法（包括承銷商、經紀交易商或代理商）以市場價格或協議價格出售。In8bio的普通股在納斯達克全球市場上市，股票代碼爲 “INAB”。截至2024年1月17日，該股的定價爲每股1.52美元。該公司專注於癌症的伽瑪三角洲T細胞療法，被視爲 “新興成長型公司” 和 “規模較小的申報公司”，上市公司的報告要求有所降低。招股說明書還強調了與投資In8bio證券相關的風險。
有用
沒用